Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model
BACKGROUND: The histamine H4 receptor (H4R) is preferentially expressed in immune cells and is a potential therapeutic target for inflammatory and autoimmune diseases. This study aimed at further exploring the role of H4R in the immunobiology of breast cancer.
METHODS: We used wild type (WT) and H4R deficient mice (KO) to evaluate whether H4R genotypes show a different distribution of T cell subsets in spleens, tumours and tumour draining lymph nodes (TDLN) in a syngeneic ErbB2-positive breast cancer model developed orthotopically with LM3 cells and its impact on tumour growth.
RESULTS: The presence of tumours had a differential impact on the distribution of T cells in TDLN from KO mice compared to WT ones. At day 21 post-inoculation (p.i.) of cells, despite no significant changes in the tumour weight, TDLN from KO mice showed a significantly increased proportion of CD8+ T cells compared to WT mice. At day 38 p.i. of cells a reduced tumour weight was evident in KO mice. This was accompanied by a decreased proportion of CD4+CD25+FoxP3+ regulatory T cells in TDLN of KO compared to WT mice. Tumour-bearing KO mice showed a better survival compared to WT mice.
CONCLUSIONS: H4R-mediated mechanisms may modulate the immune tumour microenvironment, promoting an immunosuppressive milieu. Results suggest that H4R could be explored as an immunotherapeutic target with potential benefit in combination with immunotherapy. Further preclinical and clinical studies are necessary to confirm this hypothesis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Cancer immunology, immunotherapy : CII - 70(2021), 1 vom: 04. Jan., Seite 233-244 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nicoud, Melisa B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
820484N8I3 |
|---|
| Anmerkungen: |
Date Completed 29.01.2021 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00262-020-02672-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312762003 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312762003 | ||
| 003 | DE-627 | ||
| 005 | 20240426232838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-020-02672-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM312762003 | ||
| 035 | |a (NLM)32700092 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nicoud, Melisa B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2021 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The histamine H4 receptor (H4R) is preferentially expressed in immune cells and is a potential therapeutic target for inflammatory and autoimmune diseases. This study aimed at further exploring the role of H4R in the immunobiology of breast cancer | ||
| 520 | |a METHODS: We used wild type (WT) and H4R deficient mice (KO) to evaluate whether H4R genotypes show a different distribution of T cell subsets in spleens, tumours and tumour draining lymph nodes (TDLN) in a syngeneic ErbB2-positive breast cancer model developed orthotopically with LM3 cells and its impact on tumour growth | ||
| 520 | |a RESULTS: The presence of tumours had a differential impact on the distribution of T cells in TDLN from KO mice compared to WT ones. At day 21 post-inoculation (p.i.) of cells, despite no significant changes in the tumour weight, TDLN from KO mice showed a significantly increased proportion of CD8+ T cells compared to WT mice. At day 38 p.i. of cells a reduced tumour weight was evident in KO mice. This was accompanied by a decreased proportion of CD4+CD25+FoxP3+ regulatory T cells in TDLN of KO compared to WT mice. Tumour-bearing KO mice showed a better survival compared to WT mice | ||
| 520 | |a CONCLUSIONS: H4R-mediated mechanisms may modulate the immune tumour microenvironment, promoting an immunosuppressive milieu. Results suggest that H4R could be explored as an immunotherapeutic target with potential benefit in combination with immunotherapy. Further preclinical and clinical studies are necessary to confirm this hypothesis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antitumour immunity | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Histamine H4 receptor | |
| 650 | 4 | |a T regulatory cells | |
| 650 | 7 | |a Interleukin-2 Receptor alpha Subunit |2 NLM | |
| 650 | 7 | |a Receptors, Histamine H4 |2 NLM | |
| 650 | 7 | |a Histamine |2 NLM | |
| 650 | 7 | |a 820484N8I3 |2 NLM | |
| 700 | 1 | |a Táquez Delgado, Mónica A |e verfasserin |4 aut | |
| 700 | 1 | |a Sarasola, María de la Paz |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal, Agustina |e verfasserin |4 aut | |
| 700 | 1 | |a Speisky, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Cremaschi, Graciela A |e verfasserin |4 aut | |
| 700 | 1 | |a Sterle, Helena A |e verfasserin |4 aut | |
| 700 | 1 | |a Medina, Vanina A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology, immunotherapy : CII |d 1982 |g 70(2021), 1 vom: 04. Jan., Seite 233-244 |w (DE-627)NLM012922226 |x 1432-0851 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2021 |g number:1 |g day:04 |g month:01 |g pages:233-244 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00262-020-02672-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2021 |e 1 |b 04 |c 01 |h 233-244 | ||